# Advisor Review - GPT-5.4 (R1)

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5.4
**Paper:** paper.pdf
**Timestamp:** 2026-03-11T10:30:01.755698
**Route:** OpenRouter + LaTeX
**Paper Hash:** cb92776347fe81c8
**Tokens:** 20507 in / 1832 out
**Response SHA256:** 2a9808027e8760dc

---

I checked the paper strictly for fatal errors in the four categories you specified.

Findings by category:

1. **Data-Design Alignment**
- I did **not** find a fatal mismatch between treatment timing and data coverage.
- The paper consistently states Erasmus flow data cover **2014–2023**, and all main panel analyses use years within that range.
- The pre-period definitions used for instrument construction (**2014–2016**) and long-difference design (**2014–2019 vs. 2021–2022**) are all feasible given the stated data coverage.
- I did not see any treated period or cohort defined outside the observed sample.

2. **Regression Sanity**
- I checked all reported regression tables:
  - Table `tab:first_stage`
  - Table `tab:main`
  - Table `tab:placebo`
  - Table `tab:heterogeneity`
  - Table `tab:robustness`
  - Table `tab:cross_section`
  - Table `tab:sde`
- No fatal numerical pathologies found:
  - No negative SEs
  - No `NA`, `NaN`, or `Inf`
  - No impossible \(R^2\) values
  - No coefficients \(>100\) in absolute value
  - No coefficients/SEs that are obviously explosive or collinearity artifacts under your thresholds
- All reported coefficients and SEs are numerically plausible for the units described.

3. **Completeness**
- Regression tables report **Observations (N)**.
- Main regression results include **standard errors**.
- Tables and figures referenced in the text appear to exist in the source.
- I did not find placeholder strings like `TBD`, `TODO`, `XXX`, `PLACEHOLDER`, or `NA` in tables.
- The analyses described in the methods/results sections are actually shown somewhere in the paper or appendix.

4. **Internal Consistency**
- The headline estimates in the abstract and introduction match the main results table:
  - 2SLS tertiary-share estimate around **-0.389**
  - placebo/cohort-dilution estimate around **-0.063**
- The reduced-form / first-stage / 2SLS relationship is internally consistent numerically.
- Sample periods and age-group definitions are broadly consistent across text and tables.
- I saw some small sample-size differences across tables, but nothing that is inherently impossible or clearly contradictory enough to count as a fatal inconsistency.

ADVISOR VERDICT: PASS